Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C

6Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.

Cite

CITATION STYLE

APA

Choi, J. W., Lee, J. S., Paik, W. H., Song, T. J., Kim, J. W., Bae, W. K., … Kim, J. G. (2016). Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clinical and Molecular Hepatology, 22(1), 168–171. https://doi.org/10.3350/cmh.2016.22.1.168

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free